Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on May 19, 2014, detailing amendments to its warrant agreements originally established in 2011. These amendments, entered into between May 13-16, 2014, with key financial institutions including Citibank, Credit Suisse, Goldman Sachs, and Morgan Stanley, primarily concern the reduction of outstanding warrants. The most significant impact for investors is the reduction in the total number of shares of Regeneron common stock issuable upon the exercise of these warrants. The maximum number of shares issuable has decreased from approximately 4.76 million to about 4.03 million, representing a reduction of about 15.3% per warrant holder. This adjustment was made in consideration of an aggregate payment of $143.0 million by Regeneron to the warrant holders, reflecting a strategic move to de-leverage or adjust its capital structure related to its convertible senior notes issuance from 2011.
Key Highlights
- 1Regeneron amended its 2011 warrant agreements with major financial institutions (Citibank, Credit Suisse, Goldman Sachs, Morgan Stanley).
- 2The amendments result in a 15.3% reduction in the number of warrants held by each warrant holder.
- 3The maximum number of Regeneron common shares issuable upon warrant exercise decreased from approximately 4.76 million to 4.03 million.
- 4Regeneron paid an aggregate of $143.0 million to the warrant holders in connection with these amendments.
- 5These warrants were originally issued in 2011 in connection with the company's 1.875% convertible senior notes and related hedging activities.
- 6The amendments aim to reduce the potential future dilution from these warrants.